{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:15:56Z","timestamp":1769559356711,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.eplepsyres.2009.02.016","type":"journal-article","created":{"date-parts":[[2009,3,27]],"date-time":"2009-03-27T06:01:51Z","timestamp":1238133711000},"page":"72-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: Analysis of two randomized, double-blind, placebo-controlled studies"],"prefix":"10.1016","volume":"85","author":[{"given":"William E.","family":"Rosenfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selim","family":"Benbadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Edrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Alberto","family":"Tassinari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2009.02.016_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1528-1157.2001.36400.x","article-title":"Idiopathic generalized epilepsy with generalized and other seizures in adolescence","volume":"42","author":"Andermann","year":"2001","journal-title":"Epilepsia"},{"issue":"Suppl. 2","key":"10.1016\/j.eplepsyres.2009.02.016_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1528-1167.2006.00706.x","article-title":"Idiopathic generalized epilepsies of adolescence","volume":"47","author":"Beghi","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib3","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib4","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1212\/01.WNL.0000098891.76373.15","article-title":"Idiopathic generalized epilepsy and choice of antiepileptic drugs","volume":"61","author":"Benbadis","year":"2003","journal-title":"Neurology"},{"issue":"Suppl. 9","key":"10.1016\/j.eplepsyres.2009.02.016_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1528-1167.2005.00324.x","article-title":"Practical management issues for idiopathic generalized epilepsies","volume":"46","author":"Benbadis","year":"2005","journal-title":"Epilepsia"},{"issue":"Suppl. 9","key":"10.1016\/j.eplepsyres.2009.02.016_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1528-1167.2005.00328.x","article-title":"Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs","volume":"46","author":"Bergey","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib7","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Levetiracetam N01057 Study Group","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib8","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/WNL.55.11.1757","article-title":"Exacerbation of juvenile myoclonic epilepsy with lamotrigine","volume":"55","author":"Biraben","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib9","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.52.7.1330","article-title":"A randomized, placebo-controlled study of topiramate in primary generalized tonic\u2013clonic seizures. Topiramate YTC Study Group","volume":"52","author":"Biton","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib10","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1212\/01.wnl.0000187118.19221.e4","article-title":"Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic\u2013clonic seizures","volume":"65","author":"Biton","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00323-0","article-title":"Dose\u2013response effect of levetiracetam 1000 and 2000mg\/day in partial epilepsy","volume":"48","author":"Boon","year":"2002","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/01.wnl.0000174517.21383.36","article-title":"Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies","volume":"65","author":"Crespel","year":"2005","journal-title":"Neurology"},{"issue":"Suppl. 1","key":"10.1016\/j.eplepsyres.2009.02.016_bib15","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.eplepsyres.2005.11.014","article-title":"ILAE classification of epilepsy syndromes","volume":"70","author":"Engel","year":"2006","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eplepsyres.2006.12.005","article-title":"Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate","volume":"74","author":"Fountain","year":"2007","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib17","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.0013-9580.2004.19704.x","article-title":"Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies","volume":"45","author":"Gelisse","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib18","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1212\/WNL.55.8.1106","article-title":"Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy?","volume":"55","author":"Genton","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib19","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/j.1528-1167.2006.00829.x","article-title":"Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht\u2013Lundborg disease","volume":"47","author":"Genton","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib20","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1212\/WNL.55.7.1030","article-title":"Adult myoclonic epilepsy: a distinct syndrome of idiopathic generalized epilepsy","volume":"55","author":"Gilliam","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib21","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000217916.00225.3a","article-title":"Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures","volume":"66","author":"Glauser","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.seizure.2005.02.004","article-title":"Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy","volume":"14","author":"Grosso","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1528-1157.2001.44000.x","article-title":"Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin","volume":"42","author":"Huppertz","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib24","doi-asserted-by":"crossref","unstructured":"ILAE, 1981. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 22, 489\u2013501.","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib25","doi-asserted-by":"crossref","unstructured":"ILAE, 1989. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 30, 389\u2013399.","DOI":"10.1111\/j.1528-1157.1989.tb05316.x"},{"issue":"Suppl. 9","key":"10.1016\/j.eplepsyres.2009.02.016_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2005.00309.x","article-title":"Epidemiology of idiopathic generalized epilepsies","volume":"46","author":"Jallon","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.neuropharm.2007.11.021","article-title":"SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy","volume":"54","author":"Kaminski","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib28","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/seiz.1999.0303","article-title":"Tiagabine-induced absence status in idiopathic generalized epilepsy","volume":"8","author":"Knake","year":"1999","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1059-1311(03)00139-0","article-title":"Levetiracetam treatment of idiopathic generalised epilepsy","volume":"12","author":"Krauss","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.seizure.2005.12.004","article-title":"Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study","volume":"15","author":"Labate","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.seizure.2004.10.004","article-title":"Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial","volume":"14","author":"Lagae","year":"2005","journal-title":"Seizure"},{"issue":"Suppl. 7","key":"10.1016\/j.eplepsyres.2009.02.016_bib32","first-page":"295","article-title":"Levetiracetam\u2014a helpful new drug","volume":"43","author":"Lippmann","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib33","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib34","series-title":"Antiepileptic Drugs","first-page":"419","article-title":"Levetiracetam mechanism of action in antiepileptic drugs","author":"Margineanu","year":"2002"},{"issue":"Suppl. 2","key":"10.1016\/j.eplepsyres.2009.02.016_bib35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1528-1157.44.s.2.3.x","article-title":"Overview: idiopathic generalized epilepsies","volume":"44","author":"Mattson","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1684\/j.1950-6945.2006.tb00157.x","article-title":"Identifying baseline characteristics of placebo responders versus non-responders in randomized double-blind trials of refractory partial-onset seizures","volume":"8","author":"Niklson","year":"2006","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib37","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"N166 levetiracetam study group Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"issue":"Suppl. 9","key":"10.1016\/j.eplepsyres.2009.02.016_bib38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1528-1167.2005.00313.x","article-title":"Idiopathic generalized epilepsies recognized by the International League Against Epilepsy","volume":"46","author":"Nordli","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib39","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib40","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1046\/j.1528-1157.2001.41300.x","article-title":"Pharmacokinetic study of levetiracetam in children","volume":"42","author":"Pellock","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib41","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(05)70224-6","article-title":"Birth defects after prenatal exposure to antiepileptic drugs","volume":"4","author":"Perucca","year":"2005","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib42","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1212\/WNL.45.8.1469","article-title":"Idiopathic generalized epilepsy of adolescence: are the syndromes clinically distinct?","volume":"45","author":"Reutens","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib43","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1371\/journal.pmed.0050166","article-title":"Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy","volume":"5","author":"Rheims","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib44","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.seizure.2006.05.012","article-title":"Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy","volume":"15","author":"Rocamora","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib45","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib46","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1059-1311(03)00102-X","article-title":"Non-convulsive status epilepticus associated with tiagabine therapy in children","volume":"12","author":"Skardoutsou","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2006.05.013","article-title":"Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy","volume":"71","author":"Specchio","year":"2006","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib48","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/brain\/awl047","article-title":"Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy","volume":"129","author":"Thomas","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib49","first-page":"351","article-title":"On the combination of independent two sample tests of Wilcoxon","volume":"37","author":"Van Elteren","year":"1960","journal-title":"Bull. Inst. Ins. Stat."},{"key":"10.1016\/j.eplepsyres.2009.02.016_bib50","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1046\/j.1528-1157.2003.26402.x","article-title":"EEG in adult-onset idiopathic generalized epilepsy","volume":"44","author":"Yenjun","year":"2003","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121109000631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121109000631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:21:01Z","timestamp":1760275261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121109000631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0920121109000631"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2009.02.016","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: Analysis of two randomized, double-blind, placebo-controlled studies","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2009.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}